Optimizing Treatment Strategies for Localized and Advanced Genitourinary Malignancies PRESENTED BY FOX CHASE CANCER CENTER AND THE

The management of advanced kidney, bladder, and prostate cancer is rapidly evolving, and new robotic and minimally invasive surgical techniques are now available. This CME program is designed to address the challenges

physicians face in treating these complex cases.

Presented by the nationally recognized Fox Chase Cancer Center genitourinary oncology team—comprising experts in urology, radiation therapy, and medical oncology—this program will cover the latest advancements in surgical techniques, radiation therapies, and medical treatments for both localized and advanced bladder, kidney, and prostate cancers.

Objectives:

After participating in this educational programs, learners should be able to:

- Explain some of the newest surgical techniques for bladder, kidney and prostate cancer
- Explain the newest data in radiation options for localized and advanced GU malignancies
- Describe new medical options and treatment options for advanced bladder, kidney and prostate cancer

Program Directors:



Alexander Kutikov, MD, FACS

Chair and Professor, Department of Urology Roberta R. Scheller Chair in Urologic Oncology Fox Chase – Temple Urologic Institute Provider



Daniel M. Geynisman, MD

Chief, Division of Genitourinary Medical Oncology Associate Professor, Department of Hematology/Oncology

Register Online: FoxChase.org/CME

Registration Deadline:

TEMPLE HEALTH OFFICE FOR CONTINUING MEDICAL EDUCATION.

Monday, November 18, 2024

5:45 PM - 7:00 PM Check-in & Reception

(Buffet opens at 6:30)

7:00 PM - 9:00 PM CME & Dinner

LOCATION Philadelphia Marriott Old City

One Dock Street, Philadelphia, PA 19106

INQUIRIES Lucía Tono, PhD, MEd: 215-728-3797

Lucia.Tono-Ramirez@tuhs.temple.edu

Topics & Presenters

Single Port Robotic Surgery for Genitourinary Cancer
J. Ryan Mark, MD, FACS

SABR for Oligometastatic Prostate Cancer and Localized Kidney Cancer

Jessica Karen Wong, MD, MEng

Nuances and Options for the Management of Advanced Bladder Cancer

Pooja Ghatalia, MD

Biochemically Recurrent Prostate Cancer: Treatment Paradigms and New Options

Fern Anari, MD

Adjuvant Therapy in Renal Cell Carninoma
Matthew R. Zibelman, MD

INTENDED AUDIENCE: The program is designed for medical, surgical, and radiation oncologists; urologists; radiologists; primary care physicians; fellows; residents; nurses; and other healthcare providers.

ACCREDITATION STATEMENT: The Temple Health Office for Continuing Medical Education is accredited by the Pennsylvania Medical Society to provide continuing medical education for physicians.

DESIGNATION STATEMENT: The Temple Health Office for Continuing Medical Education designates this live activity for a maximum of 2 AMA

PRA Category 1 Credits™. Physicians should only claim the credit commensurate with the extent of their participation in the educational activity.

